Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial.
about
B Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic InterventionsB-cell survival factors in autoimmune rheumatic disordersFc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeuticsProfile of atacicept and its potential in the treatment of systemic lupus erythematosusHistorical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journeyMcl-1 is essential for the survival of plasma cells.Novel therapeutic agents in clinical development for systemic lupus erythematosus.Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents.B cells and autoimmunity.Surface APRIL Is Elevated on Myeloid Cells and Is Associated with Disease Activity in Patients with Rheumatoid ArthritisAtacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial.Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges.Clinical targeting of the TNF and TNFR superfamiliesPharmacokinetics, pharmacodynamics, short term efficacy and safety of RCT-18, a novel BLyS/APRIL fusion protein, in patients with rheumatoid arthritis.Safety and efficacy of atacicept in combination with rituximab for reducing the signs and symptoms of rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled pilot trial.Non-tumor necrosis factor-based biologic therapies for rheumatoid arthritis: present, future, and insights into pathogenesis.B cells and antibodies in multiple sclerosis pathogenesis and therapy.Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity.The problem of choice: current biologic agents and future prospects in RA.B-cell targeted therapeutics in clinical development.Emerging therapies for rheumatoid arthritis.Emerging immunotherapies for rheumatoid arthritis.Update on B-cell targeted therapies for systemic lupus erythematosus.Emerging biological therapies for systemic lupus erythematosus.Tracking plasma cell differentiation and survival.Efficacy and safety implications of molecular constructs of biological agents for rheumatoid arthritis.Atacicept as an investigated therapy for rheumatoid arthritis.New treatments for inflammatory rheumatic disease.B cells biology in systemic lupus erythematosus-from bench to bedside.Emerging therapies in systemic lupus erythematous: from clinical trial to the real life.Plasma cells as an innovative target in autoimmune disease with renal manifestations.Blisibimod for treatment of systemic lupus erythematosus: with trials you become wiser.B Cell-Activating Factor (BAFF)-Targeted B Cell Therapies in Inflammatory Bowel Diseases.Beyond pan-B-cell-directed therapy - new avenues and insights into the pathogenesis of SLE.Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind studPharmacokinetics, pharmacodynamics, and tolerability of single ascending doses of RCT-18 in Chinese patients with rheumatoid arthritis.Living life without B cells: is repeated B-cell depletion a safe and effective long-term treatment plan for rheumatoid arthritis?Kv1.3 Channel Blockade Modulates the Effector Function of B Cells in Granulomatosis with Polyangiitis.Rheumatoid arthritis clinical benefits from abatacept, cytokine blockers, and rituximab are all linked to modulation of memory B cell responsesB-cell-targeted therapies in relapsing forms of MS.
P2860
Q26770664-E8AD9594-3AF3-42FD-BA58-AEBA3552C5C5Q26796484-E6BA006B-E1F8-4610-AEE7-7300F2EF4332Q26822421-C20D1906-C339-477D-8BD0-47952D409485Q26849719-32E456C3-75A6-4D69-942C-8EBC12AEF854Q26991848-771DD283-8835-450E-80E4-41493F43B971Q30412677-07C22985-60E4-4690-967F-0899568700D9Q34704902-712B7CE9-4DF4-4C0D-93B0-DDF49E1E1C43Q34960458-444FE5F0-A927-48A6-A257-C0C13D94C5C5Q35706966-17E1AABE-5415-4F2B-8C3D-B15795B21D4DQ35864231-7EC4DBC2-0BED-44DB-83B5-F5E29F121523Q36085018-EA1878C5-C01D-4221-AAA4-8CE88E236630Q36761844-B08B0D47-EBF4-4532-8A7B-2A299DDAB89BQ36762882-BDC75AA6-499D-40C2-AA6A-7113D7282688Q37030677-A39D1C67-CE36-4780-988A-02F1D5C6D32EQ37326017-65E14E11-367D-425F-8BBD-096A5C2C54CEQ37388213-7F48706F-CC95-40A6-9818-80A7246F9761Q38050398-1534F4CF-162C-4794-BD74-493F5A904B8AQ38071110-0CF67E70-4E10-4389-8901-9F2BC7B6FA20Q38082588-D903DE48-0A7D-4BDF-9F9E-F9A8684F68A1Q38097162-A3CD85E9-76BB-4827-B47F-867E18D29E91Q38110963-535553B4-30D3-4979-A017-362993D55E4AQ38188862-F7B9D09D-A8E8-4FDB-9B9E-AC4D408A7FF4Q38192656-7C323301-F0F0-4C72-AA55-E1D8BA359613Q38192683-BA93F65C-1F30-4FBC-B630-5C49219F5606Q38202086-E1E4BEB9-B6FD-406F-B165-0A559F8441CFQ38203622-FD3FAF6E-5686-489B-BF0B-586F244DDCC7Q38235570-4EA4DF4E-4FD9-4AF7-A64A-B9304440B5B8Q38266252-00E73BD7-1BC4-4D1B-99BE-16F104AF075EQ38631964-D94CC37A-EBD0-428F-97C3-279B10906942Q38747383-DC2E856C-34D1-451C-B78F-1933F294A16FQ38753491-95F04816-040A-4B5D-BAB5-282D9DA02A49Q38799791-52CAA361-7411-4951-A146-68505E8A1C93Q38961202-8EF12FDD-A241-40D3-9C13-F017B58324E8Q38979169-39D027BD-5F69-47D7-A5D0-E633FCBEB3CDQ41334797-D8FA7735-D9C5-446D-804C-445EE55846E5Q41758222-98B87176-97B7-4D68-B809-06F96662CC0DQ42229459-E7336C5C-50BB-4804-B44E-0DB83A352B86Q42368413-E528C222-72AB-4478-BCE5-DD7FEA583FE4Q42561719-9BF6A70B-2543-4D21-8D83-4A0AF8375FC3Q42631407-E759FCA2-788E-49B4-AD96-AEF8D1F143D1
P2860
Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Atacicept in patients with rhe ...... ontrolled, dose-finding trial.
@en
Atacicept in patients with rhe ...... ontrolled, dose-finding trial.
@nl
type
label
Atacicept in patients with rhe ...... ontrolled, dose-finding trial.
@en
Atacicept in patients with rhe ...... ontrolled, dose-finding trial.
@nl
prefLabel
Atacicept in patients with rhe ...... ontrolled, dose-finding trial.
@en
Atacicept in patients with rhe ...... ontrolled, dose-finding trial.
@nl
P2093
P2860
P921
P356
P1476
Atacicept in patients with rhe ...... ontrolled, dose-finding trial.
@en
P2093
C Pena Rossi
G de La Bourdonnaye
M C Genovese
P2860
P304
P356
10.1002/ART.30373
P577
2011-07-01T00:00:00Z